
Clinical trials are underway of anti-androgen drugs against high-androgen triple-negative breast cancers, and new work shows the threshold for benefit from anti-androgen therapies may be much lower than previously thought: even breast cancers with few androgen receptors benefit from anti-androgen therapy.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/oXn1p4uDk7U/150224131201.htm